Clinical trial NCT04333368: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS
Official title: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Severe Acute Respiratory Syndrome Coronavirus 2
Severe Acute Respiratory Distress Syndrome
Keywords: SARS-CoV2
COVID-19
Acute Respiratory Distress Syndrome
Cell therapy
Mesenchymal stromal cells
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2020-04-03
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Whereas the pandemic due do Covid-19 continues to spread, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Severe Acute Respiratory Distress Syndrome in 30% of patients with a 30%-60% mortality rate for those requiring hospitalization in an intensive care unit. The main physio-pathological hallmark is an acute pulmonary inflammation. Currently, there is no treatment.

Mesenchymal stem cells (MSC) feature several attractive characteristics: ease of procurement, high proliferation potential, capacity to home to inflammatory sites, anti-inflammatory, anti-fibrotic and immunomodulatory properties. If all MSC share several characteristics regardless of the tissue source, the highest productions of bioactive molecules and the strongest immunomodulatory properties are yielded by those from the Wharton's jelly of the umbilical cord. An additional advantage is that they can be scaled-up to generate banks of cryofrozen and thus readily available products. These cells have already been tested in several clinical trials with an excellent safety record.

The objective of this project is to treat intubated-ventilated patients presenting with a SARS-CoV2-related Acute Respiratory Distress Syndrome (ARDS) of less than 96 hours by three intravenous infusions of umbilical cord Wharton's jelly-derived mesenchymal stromal cells (UC-MSC) one every other day (duration of the treatment: one week). The primary endpoint is the PaO2/FiO2 ratio at day 7. The evolution of several inflammatory markers, T regulatory lymphocytes and donor-specific antibodies will also be monitored. The trial will include 40 patients, of whom 20 will be cell-treated while the remaining 20 patients will be injected with a placebo solution in addition to the standard of care. Given the pathophysiology of SARS-CoV2, it is thus sound to hypothesize that the intravenous administration of UC-MSC during the initial phase of ARDS could control inflammation, accelerate its recovery with improved oxygenation, reduced mechanical ventilation and ventilation weaning time and therefore reduced length of stay in intensive care.

The feasibility of the project is supported by the expertise of the Meary Cell and Gene Therapy Center, which is approved for the production of Advanced Therapy Medicinal Products and has already successfully prepared the first batches of cells, as well as by the involvement of a cardiac surgery team which will leverage its experience with stem cells for the treatment of heart failure to make it relevant to the Stroma-Cov-2 project.

Detailed description: General context:

As of March 13, 2020, more than 145,000 cases of 2019-nCoV infection have been confirmed with 5,500 deaths worldwide. As of March 21, 14,469 cases have been confirmed in France, of which 562 have been fatal while 1,525 patients are currently hospitalized in intensive care units. Whereas the pandemic continues to spread, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Severe Acute Respiratory Distress Syndrome in 30% of patients (Murthy et al., 2020) with a 30%-60% mortality rate. The main physio-pathological hallmark is an acute pulmonary inflammation. Currently, there is no treatment.

The objective of this project is to treat intubated-ventilated patients presenting with a SARS-CoV2-related Acute Respiratory Distress Syndrome (ARDS) of less than 96 hours by three intravenous infusions of umbilical cord Wharton's jelly-derived mesenchymal stromal cells (UC-MSC) one every other day (duration of the treatment: one week). The primary endpoint is the PaO2/FiO2 variation from baseline at day 7. The evolution of several inflammatory markers, T regulatory lymphocytes and donor-specific antibodies will also be monitored. The trial will include 40 patients, of whom 20 will be randomized to cell-treatment administered via intravenous route while the remaining 20 patients will be randomized to receive a placebo solution in addition to the standard of care. Patients will be followed up to 12 months after treatment.

State of the art:

Mesenchymal stem cells feature several attractive characteristics: ease of procurement, high proliferation potential, capacity to home to inflammatory sites, anti-inflammatory, anti-fibrotic and immunomodulatory properties. Their therapeutic benefits have been demonstrated in \> 100 animal models, including sheep. Specifically, the therapeutic effects of MSC have been demonstrated in ARDS models induced by H1N1, H5N1, H9N2 influenza virus-associated pneumoniae and were also shown to reduce bacterial-induced acute lung injury in a human model of ex vivo perfused lung (Lee et al., 2013). In the clinics, MSC have demonstrated an excellent tolerance in over 3,000 patients (Thompson et al., 2020), regardless of the dosing and delivery route. Three phase I/II trials have included patients with an ARDS and in one (START II), MSC significantly reduced pulmonary endothelial injury (Matthay et al., 2019). If all MSC share several characteristics regardless of the tissue source, the highest productions of bioactive molecules and the strongest immunomodulatory properties are yielded by those from the Wharton's jelly of the umbilical cord (Romanov et al., 2019) which can be scaled-up to generate banks of cryofrozen and thus readily available products.

So far, UC-MSC have been used in a wide variety of diseases (reviewed in Scarfe et al., 2018) and, in most cases, they have been delivered via the intravenous route which is clinically attractive because of its non invasive nature and the subsequent possibility of repeated administrations. Labeling techniques have shown that \>80% of intravenously injected MSCs are rapidly trapped in the lungs, followed by a rapid distribution of some of the injected MSCs to other tissues including liver, spleen, and inflammatory or injured sites (Brooks et al., 2018). Over all, these biodistribution patterns have been confirmed by human studies using magnetic resonance imaging (MRI), positron emission tomography (PET) and/or single-photon emission computed tomography (SPECT).2 A four-parameter model (injection rate, clearance rate, rate of extravasation and rate of intravasation) predicts that transplanted MSCs are only therapeutically active for a short period of time (probably less than 24 h) (Parekkadan and Milwid, 2010), a timescale consistent with that of the biological responses that they trigger. These assumptions are an incentive to repeated MSC administrations within a short period of time to induce a sustained therapeutic effect and has rationalized our protocol of injecting MSC one every other day over a one week-period, a design consistent with the earlier report of the benefits of delivering MSC at relatively small doses but in a repeated fashion in patients with graft-versus-host disease (Zhou et al., 2010).

Once they have homed in the lungs, MSC have been reported to first induce an inflammatory response which is detectable at the tissue level and systemically (Hoogduijn et al., 2013) and is likely due to their interaction with resident lung cells once they have accumulated in the microvasculature. This initial response is then followed by a downstream phase of reduced immune reactivity (Hoogduijn et al., 2013), the mechanisms of which have been extensively investigated. Thus, 24 hours after their intravenous infusion, most of the UC-MSC that have accumulated in the lungs are dead after their phagocytosis by monocytes and neutrophils which then migrate through the blood stream, particularly in the liver (Leibacher et al., 2017; de Witte et al., 2018). Co-culture experiments have shown that the internalization of MSC fragments by monocytes triggers a phenotypic shift which translates into the upregulation of PD-L1 and CD90 along with an increased expression of mRNA levels for IL-1β, IL-6, IL-8 and IL-10 and a decreased expression of TNF-α. Of note, monocytes polarized towards an immune-regulatory phenotype increase the expression of Foxp3+ T regulatory lymphocytes while decreasing that of activated CD4+ cells (de Witte et al., 2018). That apoptosis of intravenously infused MSC is a requirement for their immunosuppressive function is further supported by the observation that the cytotoxic activity against MSC is predictive of clinical responses in patients treated by MSC for graft-versus-host disease, i.e., the best responders are those with high cytotoxicity; in this study, the postulated mechanistic link is that phagocytes that have engulfed apoptotic MSC then produce indoleamine 2,3-dioxygenase (IDO) and thus ultimately deliver MSC immunosuppressive activity (Galleu et al., 2017).

Given the pathophysiology of SARS-CoV2, it is thus sound to hypothesize that the intravenous administration of UC-MSC during the initial phase of ARDS could control inflammation, accelerate its recovery with improved oxygenation, reduced mechanical ventilation and ventilation weaning time and therefore reduced length of stay in intensive care. This assumption is indeed supported by the recent results of a preliminary Chinese trial in which MSC (the source of which has not be specified) have been reported to improve pulmonary function and symptoms in 7 patients with COVID-19 pneumonia along with a rapid clearance of overactivated cytokine-secreting immune cells (CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells), a decrease in TNF-α circulating levels and an increase in CD14+CD11c+CD11bmid regulatory DC cells and IL-10 levels, compared with a placebo group (Leng et al., 2020).

Eligibility criteria: Inclusion Criteria:

* Male or female patient, age \> 18 years,
* Laboratory (RT-PCR)-confirmed infection with SARS-CoV2
* Diagnosis of ARDS according to the Berlin definition of ARDS
* Under invasive, non-invasive ventilation or high-flow nasal oxygen therapy (PEEP ≥ 5 cmH2O)
* Onset of ARDS \<96 hours
* Patient with French Social Security System
* Provision of a written informed consent by the designated substitute decision maker, if present. In the event of absence, the patient can be included by investigator's decision alone.

Exclusion Criteria:

* Previous history of ARDS in the last month
* Chronic respiratory diseases requiring long-term oxygen therapy and/or long-term respiratory assistance
* Allogeneic bone marrow transplantation
* Active cancer
* Liver cirrhosis with basal Child and Pugh of C
* Pulmonary fibrosis
* Patient with end-of-life decision
* Patient not expected to survive for 24 hours
* Patient who received an organ transplant
* Woman known to be pregnant or lactating
* Patient already enrolled in another interventional pharmacotherapy protocol on COVID-19
* Patient has burns to ≥15% of their total body surface area
* Patient is receiving extra-corporeal membrane oxygenation, high-frequency oscillatory ventilation or any form of extra-corporeal lung support
* Patient under tutelage

Primary outcomes:
measure: Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group
timeFrame: From baseline to day 7
Secondary outcomes:
measure: Lung injury score
timeFrame: From baseline to day 28
measure: Oxygenation index
timeFrame: From baseline to day 28
measure: In-hospital mortality
timeFrame: From baseline to day 28
measure: Mortality
timeFrame: At day 28
measure: Ventilator-free days
timeFrame: From baseline to day 28
measure: Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)
timeFrame: From baseline to day 28
measure: Cumulative use of sedatives
timeFrame: From baseline to day 28
measure: Cumulative duration of use of sedatives
timeFrame: From baseline to day 28
measure: Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)
timeFrame: From baseline to day 28
measure: Cumulative use of neuromuscular blocking agents (other than used for intubation)
timeFrame: From baseline to day 28
measure: ICU-acquired weakness and delirium
timeFrame: From baseline to day 28
measure: Treatment-induced toxicity rate and adverse events up to day 28
timeFrame: From baseline to day 28
measure: Quality of life at one year (EQ5D-3L quality of life questionnaire)
timeFrame: At 6 months and 12 months
measure: Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level
timeFrame: At day 1, 3, 5, 7 and 14
measure: Anti-HLA antibodies plasmatic dosage
timeFrame: From baseline to day 14, and at 6 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Pitié-Salpêtrière - APHP
city: Paris
country: France
facility: Hôpital Européen Georges Pompidou - APHP
Study officials:
affiliation: Hôpital Pitié-Salpêtrière - Assitance Publique - Hôpitaux de Paris
name: Antoine MONSEL, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Monsel A, Hauw-Berlemont C, Mebarki M, Heming N, Mayaux J, Nguekap Tchoumba O, Diehl JL, Demoule A, Annane D, Marois C, Demeret S, Weiss E, Voiriot G, Fartoukh M, Constantin JM, Megarbane B, Plantefeve G, Malard-Castagnet S, Burrel S, Rosenzwajg M, Tchitchek N, Boucher-Pillet H, Churlaud G, Cras A, Maheux C, Pezzana C, Diallo MH, Ropers J, Menasche P, Larghero J; APHP STROMA-CoV-2 Collaborative Research Group. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. Crit Care. 2022 Feb 21;26(1):48. doi: 10.1186/s13054-022-03930-4.
citation: Mebarki M, Iglicki N, Marigny C, Abadie C, Nicolet C, Churlaud G, Maheux C, Boucher H, Monsel A, Menasche P, Larghero J, Faivre L, Cras A. Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases. Stem Cell Res Ther. 2021 Nov 13;12(1):571. doi: 10.1186/s13287-021-02637-7.